Managing migraine with therapies targeting the CGRP pathway – a safety update
The key role of calcitonin gene-related peptide (CGRP) in the pathophysiology of migraine has led to the development of multiple therapies targeting the CGRP pathway.1,2 Several agents have been approved based on favourable efficacy and safety data from clinical trials.1 However, the extensive physiological roles of CGRP suggest that blocking this key peptide may have pote
Login to register to read this article
If you do not have a Log in, please register to be part of a big community, experience premium content and stay informed about exclusive professional events.
Log InNot registered yet? Register now